

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

<b>1. Name and Address of Reporting Person*</b> <u>Cozzens Todd C</u>  (Last) (First) (Middle) <u>C/O HEALTH CATALYST, INC.</u> <u>3165 MILLROCK DRIVE, #400</u>  (Street) <u>SALT LAKE CITY UT 84121</u>  (City) (State) (Zip)	<b>2. Issuer Name and Ticker or Trading Symbol</b> <u>Health Catalyst, Inc. [ HCAT ]</u>	<b>5. Relationship of Reporting Person(s) to Issuer</b> (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner  Officer (give title below) Other (specify below)
	<b>3. Date of Earliest Transaction (Month/Day/Year)</b> <u>07/29/2019</u>	
	<b>4. If Amendment, Date of Original Filed (Month/Day/Year)</b>	<b>6. Individual or Joint/Group Filing (Check Applicable Line)</b> <input checked="" type="checkbox"/> Form filed by One Reporting Person  Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	07/29/2019		C		43,967	A	\$0 <sup>(1)</sup>	134,331	D	
Common Stock	07/29/2019		C		6,344	A	\$0 <sup>(2)</sup>	140,675	I	By Matoaka, LLC <sup>(3)</sup>
Common Stock	07/29/2019		C		943,484	A	\$0 <sup>(4)</sup>	1,084,159	I	By Leerink Transformation Fund I, L. P. <sup>(5)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series C Preferred Stock	(1)	07/29/2019		C		43,967		(1)	(1)	Common Stock	43,967	\$0 <sup>(1)</sup>	0	D	
Series D Preferred Stock	(2)	07/29/2019		C		6,344		(2)	(2)	Common Stock	6,344	\$0 <sup>(2)</sup>	0	D	
Series E Preferred Stock	(4)	07/29/2019		C		943,484		(4)	(4)	Common Stock	943,484	\$0 <sup>(4)</sup>	0	D	

**Explanation of Responses:**

- Each share of Series C Preferred Stock automatically converted to common stock immediately prior to the closing of the Issuer's initial public offering on a one-for-one basis, and had no expiration date.
- Each share of Series D Preferred Stock automatically converted to common stock immediately prior to the closing of the Issuer's initial public offering on a one-for-one basis, and had no expiration date.
- The shares are held by Matoaka, LLC and the Reporting Person holds the voting and dispositive power over the shares.
- Each share of Series E Preferred Stock automatically converted to common stock immediately prior to the closing of the Issuer's initial public offering on a one-for-one basis, and had no expiration date.
- The shares are held by Leerink Transformation Fund I, L.P. ("Leerink") and the Reporting Person is a co-founder and Managing Partner of Leerink and holds voting and dispositive power over the shares.

**Remarks:**

/s/ Daniel Orenstein, as Attorney-in-Fact 07/29/2019

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.